Current treatment options for HER2-positive breast cancer patients with brain metastases
- 1 May 2021
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 161, 103329
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab eraThe Breast, 2013
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Lapatinib Distribution in HER2 Overexpressing Experimental Brain Metastases of Breast CancerPharmaceutical Research, 2011
- Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHERClinical Cancer Research, 2011
- Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastasesJournal of Neuro-Oncology, 2011
- Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabineAnnals of Oncology, 2010
- Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experienceBritish Journal of Cancer, 2010
- Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trialJournal of Neuro-Oncology, 2007
- Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)Annals of Oncology, 2006
- Breast Cancer Metastasis to the Central Nervous SystemThe American Journal of Pathology, 2005